Alto Ingredients vs MGP Ingredients
ALTO and CASK side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALTO and CASK compare
MGP Ingredients is the larger company, worth 1.3 times as much as Alto Ingredients ($375M against $285M).
Alto Ingredients grew revenue faster over the last twelve months (1.1% versus −15.9% for MGP Ingredients).
Alto Ingredients keeps more of each dollar of sales as profit, with a net margin of 5.5% compared with −51.4% at MGP Ingredients.
MGP Ingredients pays a dividend yielding 2.7%; Alto Ingredients does not pay one.
Alto Ingredients scores higher on the StockData Score (12 against 5 for MGP Ingredients), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALTO | CASK |
|---|---|---|
| Size and price | ||
| Market cap | $285M | $375M |
| Share price | $3.67 | $17.52 |
| Change, 1 year | 225% | −29.5% |
| Change, 5 years | −36.0% | −76.1% |
| Beta (5Y) | 0.70 | 0.68 |
| Employees | 390 | 617 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 4 (better) | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 1 (better) |
| Valuation | ||
| P/E | 5.6× | – |
| P/S | 0.3× (better) | 0.8× |
| P/B | 1.1× | 0.6× (better) |
| EV/EBITDA | 5.3× | – |
| P/FCF | 5.7× (better) | 712× |
| FCF yield | 17.5% (better) | 0.14% |
| Fair value | $10.94 | $43.03 |
| Margin of safety | 66.4% (better) | 59.3% |
| Growth | ||
| Revenue growth (TTM) | 1.1% (better) | −15.9% |
| Revenue growth, 5Y average | 0.46% | 6.3% (better) |
| Profitability | ||
| Gross margin | 6.8% | 34.7% (better) |
| Operating margin | 3.8% (better) | −57.2% |
| Net margin | 5.5% (better) | −51.4% |
| FCF margin | 5.3% (better) | 0.11% |
| Return on equity | 22.2% (better) | −34.5% |
| Return on invested capital | 9.5% (better) | −21.6% |
| Financial health | ||
| Debt / equity | 0.23 (better) | 0.57 |
| Net debt / EBITDA | 0.60 | – |
| Interest coverage | 3.8× | – |
| Current ratio | 3.19 | 6.91 (better) |
| Altman Z-score | 1.44 (better) | 1.04 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.7% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 0.25% |
| Shareholder yield | 0.00% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 46.3% | 72.3% |
| Held by insiders | 9.2% | 75.3% |
| Insider net buying, 12 months | $361K (better) | −$9.6M |
| Short interest, % of float | 8.0% | – |
Go deeper
- ALTO stock overview
- ALTO income statement
- ALTO valuation and score
- CASK stock overview
- CASK income statement
- CASK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.